×
About 190 results

ALLMedicine™ Factor X Deficiency Center

Research & Reviews  66 results

A review of the pharmacokinetics, efficacy and safety of high-purity factor X for the p...
https://doi.org/10.1111/hae.14570
Haemophilia : the Official Journal of the World Federatio... Payne J, Batsuli G et. al.

May 3rd, 2022 - Hereditary factor X (FX) deficiency (FXD) is a rare autosomal recessive bleeding disorder. Plasma-derived FX (pdFX) is a high-purity FX concentrate approved in the United States and Europe for the treatment and prophylaxis of bleeding episodes and...

Factor X Assay
https://emedicine.medscape.com/article/2085340-print

Mar 4th, 2022 - Factor X is synthesized in the liver, and vitamin K is required for its production. The reference range of factor X is 45-155% of normal.[1] Factor X levels are increased in pregnancy and in association with oral contraceptives. Defects in protein...

Factor X Assay
http://emedicine.medscape.com/article/2085340-overview

Mar 4th, 2022 - Reference Range Factor X is synthesized in the liver, and vitamin K is required for its production. The reference range of factor X is 45-155% of normal. [1] Next: Interpretation Factor X levels are increased in pregnancy and in association with o...

Genotypes and phenotypes characterization of 17 Iranian patients with inherited factor ...
https://doi.org/10.1097/MBC.0000000000001101
Blood Coagulation & Fibrinolysis : an International Journ... Fallah A, Shams M et. al.

Feb 11th, 2022 - Factor X deficiency is a rare bleeding disorder that affects almost 1 : 1000 000 people worldwide. It derives from multiple mutational changes in the factor X gene (F10). The main objective of the present study was to determine a consistent correl...

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery
https://clinicaltrials.gov/ct2/show/NCT03161626

Nov 12th, 2021 - The primary objective is to collect additional surgical data on the clinical effectiveness of Coagadex, in a post-marketing environment, for peri-operative hemostatic cover during major surgery in patients with moderate or severe hereditary factor...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  2 results

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery
https://clinicaltrials.gov/ct2/show/NCT03161626

Nov 12th, 2021 - The primary objective is to collect additional surgical data on the clinical effectiveness of Coagadex, in a post-marketing environment, for peri-operative hemostatic cover during major surgery in patients with moderate or severe hereditary factor...

A Study Investigating Treatment Factor X in People With Factor X Deficiency
https://clinicaltrials.gov/ct2/show/NCT00930176

Dec 12th, 2014 - The main objective of the study is to assess the pharmacokinetics of FACTOR X after a single dose of 25IU/kg. The secondary objectives of the study are to assess efficacy and safety of FACTOR X in the treatment of bleeding episodes over at least 6...

see more →

News  6 results

Product can reduce, prevent bleeding in kids with FXD
https://www.mdedge.com/hematology-oncology/article/185555/thrombosis/product-can-reduce-prevent-bleeding-kids-fxd
HT Staff

Jul 20th, 2017 - Vials and a syringe BERLIN—Results of a phase 3 study suggest prophylaxis with plasma-derived factor X (pdFX, Coagadex®) prevents or reduces bleeding episodes in children with moderate to severe hereditary factor X deficiency (FXD). pdFX was well.

EMA recommends therapy for bleeding disorder
https://www.mdedge.com/hematology-oncology/article/188481/pharmacy/ema-recommends-therapy-bleeding-disorder
HT Staff

Feb 8th, 2016 - Drug vials and a syringe The European Medicines Agency (EMA) has recommended marketing authorization for Coagadex to treat hereditary factor X deficiency, a rare bleeding disorder. The active substance in Coagadex is coagulation factor X, a protei.

FDA approves factor X concentrate
https://www.mdedge.com/hematology-oncology/article/187532/thrombosis/fda-approves-factor-x-concentrate
HT Staff

Oct 22nd, 2015 - Vials and a syringe The US Food and Drug Administration (FDA) has approved a factor X product derived from human plasma (Coagadex) to treat patients with hereditary factor X deficiency who are 12 years of age and older. Coagadex is approved for on.

see more →